A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
1 other identifier
observational
350
2 countries
48
Brief Summary
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Typical duration for all trials
48 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2024
CompletedFirst Posted
Study publicly available on registry
November 22, 2024
CompletedStudy Start
First participant enrolled
January 29, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 30, 2028
May 18, 2026
May 1, 2026
3.3 years
November 20, 2024
May 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Physician's Global Assessment (PGA) 0/1 response
Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response
Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation
Up to 24 months
Secondary Outcomes (9)
Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment
Baseline and at months 4, 12, 18 (optional), and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch
Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain
Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue
Baseline and months 1, 4, 12, 18 (optional) and 24
Physician's Global Assessment (PGA) score change from start of deucravacitinib treatment to follow-up
Baseline and at months 4, 12, 18 (optional), and 24
- +4 more secondary outcomes
Study Arms (1)
Participants that have initiated deucravacitinib treatment
Interventions
As prescribed by treating clinician
Eligibility Criteria
Adult patients who have been diagnosed with moderate-to-severe plaque psoriasis and who intend to start deucravacitinib treatment in France
You may qualify if:
- ≥18 years of age
- Physician-reported diagnosis of moderate to severe plaque psoriasis
- Be newly initiating deucravacitinib
- Do not object to participate
You may not qualify if:
- Currently participating in or planning to participate in an interventional clinical trial
- Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (48)
Chu Amiens Picardie - Site Sud
Amiens, 80054, France
Cabinet Médical Elisabeth Lion
Angers, 49100, France
Ch Victor Dupouy
Argenteuil, 95107, France
Local Institution - 089
Argenteuil, 95107, France
CH ARRAS
Arras, 62000, France
Cabinet Dermatologie
Bordeaux, 33200, France
Cabinet Dermatologie
Bordeaux, 33200, France
Centre Hospitalier William Morey - Hématologie
Chalon-sur-Saône, 71100, France
Local Institution - 053
Clermont-Ferrand, 63000, France
CHU Dijon
Dijon, 21000, France
Local Institution - 077
Dijon, 21000, France
CHU Grenoble Alps, Service de Dermatologie
La Tronche, 38700, France
Local Institution - 014
Le Mans, 72037, France
CH Emile Roux
Le Puy-en-Velay, 43000, France
Centre Hospitalier Lens
Lens, 62307, France
Centre de santé Filieris
Marcq-en-Barœul, 59700, France
Hopital Saint Eloi
Montpellier, 34295, France
Tagast 41
Nice, 06000, France
Ch Georges Renon
Niort, 79021, France
Ch Georges Renon
Niort, 79021, France
Hopital Caremeau
Nîmes, 30900, France
Cabinet de dermatologie
Paris, 75012, France
Local Institution - 086
Paris, 75012, France
Hôpital Privé Francheville
Périgueux, 24000, France
Centre Hospitalier de Roubaix
Roubaix, 59056, France
Centre Hospitalier de Roubaix
Roubaix, 59056, France
Local Institution - 031
Rouen, 76031, France
Local Institution - 065
Saint-Germain-en-Laye, 78100, France
Hia Begin
Saint-Mandé, 94163, France
Centre Dermatologique
Saint-Maur-des-Fossés, 94100, France
Hia Sainte Anne
Toulon, 83800, France
Hia Sainte Anne
Toulon, 83800, France
Hopital Larrey
Toulouse, 31059, France
Hopital Larrey
Toulouse, 31059, France
Hopital Larrey
Toulouse, 31059, France
Hopitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
Hopitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
Médipôle Hôpital Mutualiste
Villeurbanne, 69100, France
Médipôle Hôpital Mutualiste
Villeurbanne, 69100, France
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Cabinet Medical
La Chaux-de-Fonds, 2300, Switzerland
Local Institution - 056
La Chaux-de-Fonds, 2300, Switzerland
Local Institution - 059
La Chaux-de-Fonds, 2300, Switzerland
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2024
First Posted
November 22, 2024
Study Start
January 29, 2025
Primary Completion (Estimated)
April 30, 2028
Study Completion (Estimated)
April 30, 2028
Last Updated
May 18, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share